CTHRC1 and pancreatic neoplasm: The in vivo results showed that, compared to the control group, CTHRC1 knockdown CAFs significantly inhibited the proliferation of pancreatic cancer cells (Figure 4A), and tumor volume and weight were significantly smaller than in the control group (Figure 4B).